Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394870 | 0.92 | MEN1 (0.47) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL2970281 | 0.80 | PTGES (0.55) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL5485326 | 0.78 | MEN1 (0.41) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL27592053 | 0.77 | MEN1 (0.46) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL394925 | 0.76 | MEN1 (0.48) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL2570775 | 0.76 | POLB (0.43) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL544327 | 0.75 | MEN1 (0.59) | MEN1MAPTKMT2ACYP19A1CYP11B1 | |
| SCHEMBL2013356 | 0.75 | POLB (0.43) | MEN1MAPTKMT2ACYP19A1POLB | |
| SCHEMBL2876196 | 0.74 | MEN1 (0.61) | MEN1MAPTKMT2ACYP19A1PTGES | |
| SCHEMBL30354835 | 0.74 | MEN1 (0.61) | MEN1MAPTKMT2ACYP19A1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759721-B2 | Deuterated CFTR potentiators | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20200031776-A1 | DEUTERATED CFTR POTENTIATORS | CONCERT PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031776-A1 | DEUTERATED CFTR POTENTIATORS | CFTR, SLC26A3, SLC26A4 | MEN1 2447/4885MAPT 4862/4885KMT2A 4712/4885 |
| US-10759721-B2 | Deuterated CFTR potentiators | CFTR, SLC26A3, SLC26A4 | MEN1 2447/4885MAPT 4862/4885KMT2A 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.